Skip to Content

Regranex

Active Substance: becaplermin
Common Name: becaplermin
ATC Code: D03AX06
Marketing Authorisation Holder: Janssen-Cilag International NV
Active Substance: becaplermin
Status: Withdrawn
Authorisation Date: 1999-03-29
Therapeutic Area: Wound Healing Skin Ulcer
Pharmacotherapeutic Group: Preparations for treatment of wounds and ulcers

Therapeutic Indication

Regranex is indicated, in association with other good wound care measures, to promote granulation and thereby the healing of full-thickness, neuropathic, chronic, diabetic ulcers less than or equal to 5 cm2.

The marketing authorisation for Regranex has been withdrawn at the request of the marketing-authorisation holder.

Source: European Medicines Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide